References
- Burdo JR, Connor JR. (2003). Brain iron uptake and homeostatic mechanisms: an overview. Biometals 16:63–75.
- Celia C, Trapasso E, Cosco D, et al. (2009). Turbiscan lab® expert analysis of the stability of ethosomes® and ultradeformable liposomes containing a bilayer fluidizing agent. Colloids Surf B Biointerfaces 72:155–60.
- De Groot AS, Scott DW. (2007). Immunogenicity of protein therapeutics. Trends Immunol 28:482–90.
- Donahue MJ, Blakeley JO, Zhou J, et al. (2008). Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches. Magn Reson Med 59:336–44.
- Ernsting MJ, Tang WL, MacCallum NW, Li SD. (2012). Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials 33:1445–54.
- Gao Y, Liu XL, Li XR. (2011). Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine 6:1017–25.
- Guerrero-Cázares H, Tzeng SY, Young NP, et al. (2014). Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivo. ACS Nano 8:5141–53.
- Guilhaumou R, Solas C, Rome A, et al. (2010). Validation of an electrospray ionization LC/MS/MS method for quantitative analysis of vincristine in human plasma samples. J Chromatogr B 878:423–7.
- Hainfeld JF. (1992). Uranium-loaded apoferritin with antibodies attached: Molecular design for uranium neutron-capture therapy. Proc Natl Acad Sci USA 89:11064–8.
- He D, Marles-Wright J. (2015). Ferritin family proteins and their use in bionanotechnology. N Biotechnol 32:651–7.
- Hoffman JA, Giraudo E, Singh M, et al. (2003). Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4:383–91.
- Hu QY, Gao XL, Kang T, et al. (2013). CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels. Biomaterials 34:9496–508.
- Hu K, Li J, Shen Y, et al. (2009). Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 134:55–61.
- Jarvinen TA, Ruoslahti E. (2007). Molecular changes in the vasculature of injured tissues. Am J Pathol 171:702–11.
- Joyce JA. (2005). Therapeutic targeting of the tumor microenvironment. Cancer Cell 7:513–20.
- Kessler T, Bieker R, Padró T, et al. (2005). Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res 11:6317–24.
- Khodarev NN, Yu J, Labay E, et al. (2003). Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 116:1013–22.
- Kilic M, Ozlu E, Calis S. (2011). A novel protein-based anticancer drug encapsulating nanosphere: apoferritin-doxorubicin complex. J Biomed Nanotechnol 8:1–7.
- Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65–81.
- Li L, Fang CJ, Ryan JC, et al. (2010). Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci USA 107:3505–10.
- Li MY, Li ZP, Yang Y, et al. (2016). Thermo-sensitive liposome co-loaded of vincristine and doxorubicin based on their similar physicochemical properties had synergism on tumor treatment. Pharm Res 33:1881–98.
- Li L, Munoz-Culla M, Carmona U, et al. (2016). Ferritin-mediated siRNA delivery and gene silencing in human tumor and primary cells. Biomaterials 98:143–51.
- Li XY, Zhao Y, Sun MG, et al. (2014). Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials 35:5591–604.
- Lown JW. (1993). Discovery and development of anthracycline antitumor antibiotics. Chem Soc Rev 22:165–76.
- Moghimi SM, Symonds P, Murray JC, et al. (2005). A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 11:990–5.
- Nativo P, Prior IA, Brust M. (2008). Uptake and intracellular fate of surface-modified gold nanoparticles. ACS Nano 2:1639–44.
- Pang Z, Gao H, Yu Y, et al. (2011). Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes. Int J Pharm 415:284–92.
- Siddik ZH. 2002. Mechanisms of action of cancer chemotherapeutic agents: DNA interactive alkylating agents and antitumour platinum-based drugs. In: Alison MR, ed. The cancer handbook. London: Nature Publishing Group, 1125–313.
- Symonds P, Murray JC, Hunter AC, et al. (2005). Low and high molecular weight poly(L-lysine)s/poly(L-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. Febs Lett 579:6191–8.
- Tosi G, Belletti D, Pederzoli F, Rozi B. (2016). Apoferritin nanocage as drug reservoir: is it a reliable drug delivery system? Expert Opin Drug Deliv 13:1341–3.
- Wong HL, Wu XY, Bendayan R. (2012). Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 64:686–700.
- Xin HL, Jiang XY, Gu JJ, et al. (2011). Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32:4293–305.
- Zhang B, Shen S, Liao Z, et al. (2014). Targeting fibronectins of glioma extracellular matrix by CLT1 peptide-conjugated nanoparticles. Biomaterials 35:4088–98.
- Zhao ZX, Gao SY, Wang JC, et al. (2012). Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery. Biomaterials 33:6793–807.
- Zhen ZP, Tang W, Chen HM, et al. (2013). RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano 7:4830–7.